At present, studies have reported that the CX3CL1/CX3CR1 biological axis can affect the drug resistance of ovarian cancer cells by mediating changes in the levels of inflammatory factors and cytokines, thereby maintaining the sensitivity of tumor cells to platinum drugs (Liu et al., 2021; Miao et al., 2020). This evidence concerns the gene CX3CL1 and ovarian cancer.